United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream is super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - depakote (divalproex sodium) is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. the efficacy of depakote was established in 3-week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania [see clinical studies ( 14.1 ) ] . the safety and effectiveness of depakote for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. therefore, healthcare providers who elect to use depakote for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. depakote is indicated as monotherapy and adjunctive therapy in

United States - English - NLM (National Library of Medicine)

conopco inc. d/b/a/ unilever - aluminum chlorohydrate (unii: hpn8mzw13m) (aluminum chlorohydrate - unii:hpn8mzw13m) - aluminum chlorohydrate 23.3 g in 100 g - antiperspirant - reduces underarm wetness

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections - rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. - respiratory tract infections caused by mycoplasma pneumoniae . - lymphogranuloma venereum caused by chlamydia trachomatis . - psittacosis (ornithosis) caused by chlamydophila psittaci . - trachoma caused by

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections - rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. - respiratory tract infections caused by mycoplasma pneumoniae . - lymphogranuloma venereum caused by chlamydia trachomatis . - psittacosis (ornithosis) caused by chlamydophila psittaci . - trachoma caused by

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole tablets are indicated for the treatment of -   schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.'s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.'s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)].             pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonate

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22), sucrose (unii: c151h8m554) (sucrose - unii:c151h8m554), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), gallic acid monohydrate (unii: 48339473ot) (gallic acid - unii:632xd903sp), indole (unii: 8724fjw4m5) (indole - unii:8724fjw4m5), garlic (unii: v1v998dc17) (garlic - u - for temporary relief of symptoms related to candida albicans infection such as nausea, drowsiness, lethargy, confusion, vaginal discharge, sensitivities to foods and mucous congestion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to candida albicans infection such as nausea, drowsiness, lethargy, confusion, vaginal discharge, sensitivities to foods and mucous congestion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia (see warnings). experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of bupivacaine hydrochloride in these patients. bupivacaine hydrochloride is not recommended for intravenous regional anesthesia (bier block) (see warnings). the routes of administration and indicated bupivacaine hydrochloride concentrations are: (see dosage and administration for additional information.) standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of bupivacaine hydrochloride. bupivacaine hydrochloride is contraindicated in obstetrical paracervical block anesthesia. its use in this techniqu

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: - levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. - levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.3)

United States - English - NLM (National Library of Medicine)

greer laboratories, inc. - platanus occidentalis pollen (unii: e03u1k03lk) (platanus occidentalis pollen - unii:e03u1k03lk) - non-standardized allergenic extracts are indicated for: - skin test diagnosis of patients with a clinical history of allergies to one or more of the specific non-standardized allergens. - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by appropriate positive skin tests or by in vitro testing for allergen-specific ige antibodies. food extracts have not been proven safe or effective in allergen immunotherapy. non-standardized allergenic extracts are contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic or local allergic reaction to an allergen extract. 8.1 pregnancy risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. there are no human or animal data to establish the presence or absence of non-standardized aller